Immunovant Sciences News Today

Before U.S. markets open Thursday morning, 31 companies are scheduled to report quarterly earnings results. The following table is based on data from Briefing.com and includes a consensus forecast in dollars for quarterly earnings per share and EPS reported last year, and the consensus forecast for quarterly revenue in thousands of dollars. Companies marked with […]

Before U.S. markets open Friday morning, 40 companies are scheduled to report quarterly earnings results. No earnings reports are scheduled for release Friday afternoon. The following table is based on data from Briefing.com and includes a consensus forecast in dollars for quarterly earnings per share and EPS reported last year, and the consensus forecast for […]

The SEC case is the latest to highlight the risks investors run when they get involved with "blank check" companies.

  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Companys securities between October 2, 2019 and February 1, 2021, inclusive (the Class Period), are encouraged to con...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the "Class Period"), of the important April 20, 2021 lead plaintiff deadline.

(1) NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the "Company") (NASDAQ: IMVT; HSACU; HSAC; and HSACW) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-00918, is on behalf of a class consisting of all persons and entities other than De...

LOS ANGELES, CA / ACCESSWIRE / February 28, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor... | March 4, 2021

Health your username February 22, 2021 A shareholder has sued Immunovant, Inc. and several of its officers after the company’s stock price tumbled earlier this month. The approximately 42% drop reportedly occurred after the clinical-stage biopharmaceutical company announced a “voluntary pause” of the trial of its myasthenia gravis and thyroid eye disease drug, known as IMVT-1401, in light of concerning side effects. According to the Feb. 19 Eastern District of New York complaint, Immunova...

(2) NEW YORK, Feb. 20, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the "Company") (NASDAQ: IMVT; HSACU; HSAC; and HSACW) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-00918, is on behalf of a class consisting of all persons and entities other than D...